WRITTEN BY Frederick W. Sabido, MBA; Editor: Frederick L.H. Sabido, MD, FACS
Welcome to The Wellness Ledger
A weekly health led newsletter grounded in evidence-based medicine along with prospective randomized controlled trials (RCTs) by medical specialists. Our goal is to help you make sense of complex scientific information and turn it into clear, evidenced based practices you can use to make better decisions about your health and wellness.
In September 2023, the FDA effectively banned pharmacies from making a list of popular peptides. Then it watched what happened.
Imports of hormone and peptide compounds from China hit $328 million in the first three quarters of 2025. Over the same nine months of the prior year 2024, the figure was $164 million. The ban did not halve demand. Demand actually doubled.
Most of it arrives labelled research use only, a designation that lets a substance be sold legally on the condition nobody puts it in a human. Buyers reconstitute the powder at home and inject it. Roughly 70% of the factories sit in a single Chinese province, Guangdong.
THE DETAIL THAT SAYS THE MOST
Retail sale of these peptides is illegal inside China too. The factories are not serving a domestic market. They are aimed at foreign buyers, which is why sellers advertise in English on Chinese social platforms.
By February 2026 the agency had read the same numbers and reversed course, saying the restrictions were pushing people toward the gray market rather than away from peptides. That reversal is what put seven compounds in front of an advisory panel in July.
The panel recommended six of them. The FDA's own scientists had recommended against all seven.
Sources: US customs data reported by the New York Times, January 2026. FDA briefing documents, PCAC July 23-24 2026, docket FDA-2025-N-6895.
MEDICAL TREND SNAPSHOT
What Was Actually Being Decided at White Oak
FIRST, THE BASICS
A peptide is a short chain of amino acids, the same building blocks proteins are made from, just far fewer of them.
The seven in front of the panel are synthetic copies of fragments the body makes in small amounts, sold on the promise that more of the fragment means faster healing, better sleep, or a longer life. None is approved as a drug in the United States to date.
Compounding is separate from approval. It lets a licensed pharmacy mix a drug to order for one named patient holding a prescription. The panel was ruling on that, not on whether these peptides work.
6 of 7 recommended | 0 of 7 backed by FDA staff | $328m imports from China, first 9 months of 2025 |
|---|
Only Emideltide, better known as DSIP, was turned down. Nothing about the vote is binding, and nothing became legal.
Day-two margins on Epitalon and DSIP are still reported inconsistently across outlets, so we have left them out. Vote record via FDA PCAC meeting materials.
HOW WE GOT HERE
Three years of policy reversal, in six dates
Sept 2023
FDA moves a group of popular peptides into Category 2 of its interim bulk substances list, meaning significant safety concerns. Compounding pharmacies can no longer make them.
2024
The restricted list grows past a dozen compounds. The advisory committee reviews CJC-1295 and Ipamorelin and votes against both. They stay restricted.
2024 to 2025
Enforcement widens. Warning letters go to vendors including Prime Peptides, Xcel Peptides and SwissChems. Seven or more research-chemical companies shut down. Demand does not fall.
Feb 2026
HHS signals that the restrictions went too far and were pushing patients toward the gray market rather than away from peptides.
Apr 23 2026
Twelve peptides come off Category 2 to be formally evaluated. This is a queue position, not permission.
Jul 23-24 2026
The panel reviews seven and recommends six, over the objection of FDA's own reviewers.
THE SEVEN, SIDE BY SIDE
What Each peptide Is, and What Stands Behind it
PEPTIDE | WHAT IT IS | PANEL VOTE | THE HUMAN EVIDENCE |
|---|---|---|---|
15-amino-acid fragment of a protein in gastric juice | 8 to 6, one abstain | One randomized trial, 53 patients, did not beat placebo to date | |
KPV | 3-amino-acid tail of alpha-MSH, a hormone that calms inflammation | 8 to 6, one abstain | None to date. Not a trial, not a case report |
Synthetic version of thymosin beta-4, which organises the cell skeleton | 8 to 6, one abstain | None for the reviewed continuous use. Typically used syngergistically with BPC-157. | |
MOTS-c | A peptide encoded inside mitochondrial DNA, not the cell nucleus | 7 to 5, two abstain | None for obesity or osteoporosis. more on our view of MOTs-c here. |
Semax | Russian analogue of ACTH(4-10), a fragment of a stress hormone | 8 to 5 | Three decades of Russian stroke trials |
Epitalon | 4-amino-acid peptide copied from a bovine pineal gland extract | Reported inconsistently | None for the synthetic version |
Emideltide | Also called DSIP, first isolated from sleeping rabbits in 1977 | Rejected | Oldest human record of the seven |
Vote tallies reconciled across multiple trade outlets. Evidence assessments from the FDA staff review, docket FDA-2025-N-6895.
CLINICAL BREAKDOWN
What FDA Scientists Found Before The Vote
The BPC-157 file is the one worth reading, because BPC-157 is the peptide most people have actually heard of.
It was isolated from human gastric juice, and its selling point is durability. Most peptides fall apart within minutes in stomach acid. This fifteen-amino-acid fragment does not, which is why it was pulled out of the protective protein fraction in the first place.
In animals it upregulates VEGF and activates the VEGFR2 receptor, the main switch for growing new blood vessels into injured tissue. New vessels mean oxygen and nutrients reach a healing tendon faster. That mechanism is real, repeatedly demonstrated, and the reason the compound has a following. We have a whole write up talking about it here.
[PRECLINICAL/ANIMAL]
It is also almost entirely animal work.
Both companies that nominated BPC-157 withdrew their nominations before the meeting. FDA evaluated it anyway.
Reviewers found one human efficacy study for the proposed use: a randomised, double-blind, placebo-controlled trial of 53 ulcerative colitis patients, published only as a conference abstract.
[HUMAN RCT]
THE RESULT ALMOST NOBODY REPORTED
Disease activity dropped 3.2 points on BPC-157 and 1.6 points on placebo. The difference between the groups was 1.6 points, with a 95% confidence interval running from -4.84 to 1.62.
That interval crosses zero, which means the true effect could just as easily be nothing. The one randomised human trial of BPC-157 did not separate from placebo.
There is a second problem the animal data hides. BPC-157 clears the blood in about 15 minutes in rats and roughly 5 minutes in dogs, and after a rectal dose in humans it was undetectable in plasma altogether.
That does not automatically mean it fails. A drug can act locally where it lands. It does mean the systemic healing story people tell about it, tendons repaired from an injection in the abdomen, has no measured number pharmacologically behind it in humans to date, and that data will give us more of a true story in regards to efficacy. Remember, signalling is what promotes angiogenesis, so having a concentration in this respect may not explain exactly how benefits are being recorded in anecdotal evidence.
FDA could not confirm what was in the vials either. The certificates of analysis submitted with the nominations listed purity and nothing else. No impurity limits, no endotoxin testing, no aggregation data.
Sources: Ruenzi et al., Gastroenterology 2005;128:A584 (n=53, 80 mg enema, 2 weeks). Half-life and pharmacokinetic data via the FDA briefing document for BPC-157.
THE EVIDENCE, PEPTIDE BY PEPTIDE
KPV, Semax and Epitalon, the three we have not covered before
KPV: a good mechanism, delivered the wrong way
KPV is the last three amino acids of alpha-MSH, a hormone that switches off inflammation. The full hormone is too promiscuous to use as a drug. The tail end keeps the anti-inflammatory action without the rest.
It gets into gut lining cells through a transporter called PepT1 and blocks NF-kB, the master switch that turns inflammatory genes on. In rodent colitis models it works, and the mechanism is coherent.
[PRECLINICAL/ANIMAL]
But those animals received KPV as a rectal hydrogel or packed into nanoparticles engineered to survive the journey to the colon. Nominators proposed a 0.1% topical cream for skin.
Those are not the same intervention. FDA found zero human studies of any kind for KPV. Not a trial, not a case report, not even pharmacokinetic data.
[REGULATORY]
Semax: the one with real clinical mileage
Semax is a modified fragment of ACTH, the stress hormone that tells the adrenal glands to make cortisol. Russian chemists cut out the hormonal part and kept a seven-amino-acid piece that acts on the brain instead, raising BDNF, the growth factor neurons use to survive and rewire.
It has been registered in Russia since the 1990s and given to stroke patients for three decades. Trials used 12 to 18 mg a day intranasally in the two weeks after an ischemic stroke and reported faster neurological recovery.
Later work reported better Barthel scores, the scale measuring whether someone can dress, wash and feed themselves again. That is a functional endpoint, not a blood marker standing in for one, and it is the kind of outcome most peptide research never gets near.
[HUMAN, MIXED DESIGN]
Those are real endpoints, not surrogates. This is the most human evidence of any of the seven.
The catch is design. The most-cited follow-up was open-label and non-randomised, and reports no effect sizes. None of it has been replicated outside Russia. That is not the same as saying it is wrong. However, it does mean nobody independent has checked.
[HUMAN, NON-RANDOMISED]
WORTH WATCHING
FDA flagged animal evidence that Semax has anticoagulant activity. Stroke comes in two kinds, one caused by a clot and one by a bleed, and they are treated in opposite directions. A thinner given to the wrong one makes it worse.
Epitalon: the mechanism is also the risk, and the dose is inaccurate
Every time a cell divides, the caps on the ends of its chromosomes get shorter. Those caps are telomeres. When they run down, the cell stops dividing. That ceiling is the Hayflick limit, and it is one reason tissue ages.
Telomerase rebuilds those caps. Epitalon is sold on the claim that it switches telomerase back on.
[MECHANISTIC]
Which is exactly the problem. Reactivated telomerase is a defining feature of cancer cells and it is how they divide without limit. A compound that lifts the Hayflick ceiling in healthy tissue would lift it in damaged tissue too. There are no carcinogenicity studies.
AND THE DOSE EVERYONE USES IS THE WRONG ONE
Ask a vendor for the dose and you will hear 5 to 10 mg a day. That traces to a real study of 266 elderly patients followed six to eight years, reporting a 1.6 to 1.8-fold reduction in mortality.
The study did not use Epitalon. It used Epithalamin, a crude extract from bovine pineal glands, at 10 mg. Epitalon is the single purified peptide later isolated from that mixture. One is a soup, the other is one ingredient from it.
In animals the purified peptide is active at concentrations 1,000 to 5,000 times lower than the extract. A 2026 analysis calls the standard dose a translational error and argues the human range has to be rebuilt in micrograms.
So nobody knows the cancer risk, and nobody knows what exposure they would be asking about either in this specific case.
Sources: Gusev et al., Zh Nevrol Psikhiatr 2018 (PMID 29798983) (n=110, open-label). Gusev et al., acute ischemic stroke (PMID 11517472). Epitalon dose data: Khavinson and Morozov, Neuroendocrinol Lett 2003 (PMID 14523363) (n=266). Anisimov et al., Biogerontology 2003 (potency). Jung, Aging Pathobiol Ther 2026.
PREVIOUSLY IN THE LEDGER
BPC-157, TB-500 and MOTS-c, What This Hearing Adds
We have already run the long version on two of these. Our BPC-157 and TB-500 issue covered the mechanism, the animal evidence and the stack. Nothing in the FDA files overturns it.
MOTS-c is the odd one out, and worth understanding. Almost every peptide in your body is encoded in the nucleus. MOTS-c is encoded inside mitochondrial DNA, the small separate genome your cells inherited from an ancient bacterium.
It appears to work as a stress signal, telling the rest of the cell that the mitochondria are under metabolic strain and triggering AMPK, the same energy-sensing pathway that exercise and metformin act on. That is a genuinely interesting piece of biology, which is part of why it has a following.
It has the most conventional scientific pedigree of the seven, discovered in a university laboratory rather than a supplement market. It still drew the narrowest margin of day one, because no human efficacy data exists for the indications reviewed.
[REGULATORY]
One update applies to all three. BPC-157, TB-500 and MOTS-c are all on the World Anti-Doping Agency prohibited list. If you compete in anything drug-tested, all three are disqualifying.
THE NUMBER THAT MATTERS
The finding that should change your behavior
Almost nobody is covering this part, and it is why the vote might still turn out well.
Two sports medicine researchers ran 6,441 independent test reports on gray-market peptides against pharmaceutical quality standards.
[PRODUCT ANALYSIS - PREPRINT, NOT PEER REVIEWED]
41.6%
of samples failed on dose accuracy, purity or identity against the standard used for compounded medicines. Against the stricter manufactured-drug standard, 71.1% failed. About one vial in forty-two contained none of the peptide on the label.
TB-500 was the worst of the group. Only 22.5% of samples passed, and one vial in ten did not contain TB-500 at all.
Source: Mendias and Awan, Preprints.org 2026, doi 10.20944/preprints202604.1748 (6,441 reports, 14 compounds). Preprint, not yet peer reviewed.
THE PROTOCOL
What to understand while the rulemaking plays out
Expect years, not months.
A recommendation is not a rule. The FDA must still publish a proposed rule, run a comment period, and publish a final rule, and it can decline at any point. A second panel meets before the end of February 2027 on five more compounds, including LL-37 and GHK-Cu.
The cost gap is smaller than you think.
For the one compound with clean pricing, a 24-week course ran $122 gray market against $266 compounded. Around $144 more, for a supply chain with inspections and protocols behind it.
Check the WADA list first.
If you compete in anything drug-tested, BPC-157, TB-500 and MOTS-c are all disqualifying.
Tell your doctor.
The only adverse event reports FDA holds on BPC-157 exist because somebody filed them. Two involved products bought as research chemicals. Nobody can help with a reaction to something they do not know you take.
READER'S PULSE
What is Your Take on Peptides After This Hearing?
SAVE THIS
REFERENCES
Every claim above traces to one of these. Links go to the primary document, not a summary of it.
Ruenzi et al., Gastroenterology 2005;128:A584 is a conference abstract with no online record. It is reported here as FDA characterised it in the briefing document above.
The Wellness Ledger is written for readers who want the real evidence, not the marketing version of it. Nothing here is medical advice. Talk to your own doctor before starting or stopping any treatment.
LIKED THE ISSUE?
Get the Printable Version👉
